Topics

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

15:39 EDT 25 Jun 2019 | OncLive

Enzalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer demonstrated significantly improved radiographic progression-free survival versus placebo plus ADT, regardless of baseline prostate-specific antigen levels, according to expanded findings from the ARCHES study.

Original Article: Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer"

Quick Search

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...